In Section A, members will receive diverse doses and schedules of oral ABBV-744 pill to identify Risk-free dosing routine. More participants is going to be enrolled at the recognized monotherapy dosign routine. In Section B, members will get oral ruxolitinib and ABBV-744 will be specified as "include-on" therapy. In Segment https://abbv-744-and-other-brd4-i80134.bloggactif.com/33019089/helping-the-others-realize-the-advantages-of-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc